Key Takeaways

24.2% weight loss at 48 weeks with 12mg dose, the highest efficacy seen in any GLP-1 class medication trial
93% of participants on 12mg achieved ≥15% weight loss; 100% achieved ≥5%
Weight loss was dose-dependent: 4mg (-17.1%), 8mg (-22.8%), 12mg (-24.2%) at 48 weeks
Results appeared early (visible by week 4) and continued throughout the 48-week trial
Beyond weight: significant improvements in blood pressure, lipids, liver fat, and glycemic control

⚠️ Investigational Drug: Retatrutide is not FDA-approved. These results come from Phase 2 clinical trials published in NEJM (2023) and ongoing Phase 3 trials. Lilly plans to file with the FDA in Q1 2027, and approval would follow FDA review. In the US, the routes available today are a clinical trial or Lilly's expanded access program (ClinicalTrials.gov NCT07629401), which a doctor must request, for adults with a BMI of 35 or more whose obesity has not responded to the highest available dose of current weight-loss treatment, who have two or more serious obesity-related complications, and who cannot join a trial. The FDA states retatrutide cannot be used in compounding under federal law, so compounding pharmacies cannot lawfully supply it.

When Eli Lilly published retatrutide's Phase 2 trial results in the New England Journal of Medicine in June 2023, the numbers got attention: participants on the highest dose lost an average of 24.2% of their body weight over 48 weeks. That's roughly 58 pounds for someone starting at 240 pounds, making it the most effective weight loss medication tested to date.

But raw numbers don't tell the whole story. This guide breaks down retatrutide results in detail: how weight loss progressed over time, what happened to body composition, which metabolic markers improved, and what you can realistically expect if you're considering this medication when it becomes available.

All data comes from published clinical trials and ongoing Phase 3 research. For dosing protocols and titration schedules, see the retatrutide dosing guide.

Phase 2 Trial: Study Design and Population

The landmark Phase 2 trial enrolled 338 adults with obesity (BMI ≥30) or overweight with comorbidities (BMI ≥27). About 52% were men, average baseline BMI was 38.8, and average weight was 109 kg (240 lbs).

Trial Structure

Duration: 48 weeks of treatment
Participants: 338 adults randomized 2:1:1:1:1:2:2 to placebo or retatrutide groups
Doses tested: 1mg, 4mg, 8mg, 12mg (all with slow titration from 2mg starting dose)
Lifestyle intervention: All participants received counseling on diet (500 kcal/day deficit) and exercise (≥150 min/week)
Primary endpoint: Percent weight change at 24 weeks
Key secondary endpoints: Weight change at 48 weeks, proportion achieving ≥5%, ≥10%, ≥15% loss

The trial used a slow titration protocol to minimize side effects: all groups except the 1mg dose started at 2mg weekly and escalated every 4 weeks. This approach, borrowed from tirzepatide trials, proved effective at improving tolerability.

📊 Important context: These results were achieved with lifestyle intervention (diet and exercise counseling) in addition to medication. Retatrutide is not a magic pill. Best results come from combining medication with behavioral changes.

Retatrutide Weight Loss Results by Dose

Retatrutide dose-response chart showing weight loss by dose from 1mg to 12mg at 48 weeks

Weight loss was strongly dose-dependent. Higher doses produced much better results, and all doses outperformed placebo by a wide margin.

48-Week Weight Loss Results

Dose Group	Mean Weight Loss (%)	Mean Weight Loss (kg / lbs)	≥5% Loss	≥15% Loss
Placebo	-2.1%	-2.0 kg / 4.4 lbs	27%	2%
1mg	-8.7%	-8.7 kg / 19.2 lbs	85%	28%
4mg	-17.1%	-17.5 kg / 38.6 lbs	92%	60%
8mg	-22.8%	-24.2 kg / 53.4 lbs	100%	75%
12mg	-24.2%	-24.0 kg / 52.9 lbs	100%	83%

Source: Jastreboff AM, et al. NEJM 2023

💡 What this means:

Even the lowest dose (1mg) produced clinically meaningful weight loss (-8.7%)
The 12mg dose showed no plateau at 48 weeks; weight loss was still continuing
100% of participants on 8mg or 12mg achieved at least 5% weight loss (the threshold for health benefits)
83% on 12mg achieved ≥15% weight loss, which is considered exceptional

How Retatrutide Compares to Other GLP-1 Medications

Weight loss comparison between semaglutide, tirzepatide, and retatrutide clinical trial results

Medication	Mechanism	Max Dose	Mean Weight Loss	Trial Duration
Retatrutide	Triple: GLP-1/GIP/Glucagon	12mg weekly	-24.2%	48 weeks
Tirzepatide (Mounjaro/Zepbound)	Dual: GLP-1/GIP	15mg weekly	-20.9%	72 weeks
Semaglutide (Wegovy)	Single: GLP-1	2.4mg weekly	-14.9%	68 weeks

Each additional receptor target correlates with greater weight loss. That said, these trials used different populations and durations, so direct comparison has limits. Head-to-head trials are ongoing. For detailed comparisons, see our retatrutide vs tirzepatide and retatrutide vs semaglutide guides.

Timeline of Retatrutide Results: Week by Week

The trial data shows weight loss beginning early and continuing throughout treatment. Here's how it breaks down.

Weight Loss Progression Over 48 Weeks (12mg Dose)

Timepoint	Cumulative Weight Loss	What's Happening
Week 4	~2-3%	Initial appetite suppression kicks in; mostly water weight
Week 12	~8-10%	Consistent fat loss; metabolic changes become measurable
Week 24	~17.5%	Approaching steady state at max dose; side effects improving
Week 36	~21%	Weight loss continues without plateau
Week 48	-24.2%	Trial endpoint; no sign of plateau yet

⏱️ Key insight: Weight loss velocity was fastest between weeks 12-24 when participants reached higher doses. The trial ended at 48 weeks with weight still declining, suggesting results may continue beyond one year. Phase 3 trials will test longer durations.

Realistic Month-by-Month Expectations

Based on trial data, here's what someone starting at 240 lbs (109 kg) might expect on the 12mg dose trajectory:

Month 1 (2mg): 5-7 lbs lost. Mild appetite reduction, possible GI side effects
Month 2 (still 2mg): Additional 3-5 lbs. Body adjusting, side effects improving
Month 3 (4mg): Additional 6-8 lbs. Appetite suppression more noticeable
Month 4 (4mg): Additional 5-7 lbs. Weight loss steady
Month 5 (8mg): Additional 7-10 lbs. Side effects may temporarily return
Month 6 (8mg): Additional 6-8 lbs. Cumulative loss ~40 lbs
Months 7-12 (12mg): Additional 12-18 lbs. Final total ~53 lbs (24.2%)

These numbers represent averages. Individual results vary based on starting weight, adherence to lifestyle changes, genetics, and dose tolerance. Use our retatrutide calculator to model your specific dosing schedule.

Body Composition Changes: Fat vs Muscle Loss

Rapid weight loss always raises concerns about muscle loss. The Phase 2 trial included DEXA scans to measure changes in fat mass and lean mass.

Body Composition Results (12mg Dose, 48 Weeks)

Measurement	Change from Baseline	% of Total Weight Lost
Total Weight Loss	-24.0 kg (-52.9 lbs)	100%
Fat Mass Reduction	-17.8 kg (-39.2 lbs)	~74%
Lean Mass Reduction	-6.2 kg (-13.7 lbs)	~26%

⚖️ Context on lean mass loss:

Some lean mass loss (25-30%) is typical with any significant weight loss, including bariatric surgery
Lean mass includes muscle, water, bone, and organs, not just muscle
The glucagon component may help preserve muscle compared to GLP-1-only drugs
Resistance training + adequate protein (1.0-1.2g/kg daily) can minimize muscle loss

Visceral Fat Reduction

Retatrutide also led to large reductions in visceral adipose tissue (VAT), the fat surrounding internal organs that's linked to metabolic disease. At 48 weeks on 12mg:

Visceral fat: -42% reduction (more than total weight loss percentage)
Liver fat: -50% reduction based on imaging studies
Subcutaneous fat: -28% reduction

The fact that visceral and liver fat dropped faster than overall weight helps explain retatrutide's metabolic improvements. The glucagon component likely drives this through increased hepatic fat oxidation.

Model Your Retatrutide Results

Use our free calculator to visualize drug levels and plan your dosing schedule based on clinical trial data.

Retatrutide Calculator Reconstitution Tool

Metabolic Improvements Beyond Weight Loss

Weight loss gets the attention, but retatrutide also improved multiple metabolic markers. Some of these changes went beyond what weight loss alone would explain, pointing to direct metabolic effects from the triple-agonist mechanism.

Cardiometabolic Changes (12mg Dose, 48 Weeks)

Marker	Baseline (Average)	Change at 48 Weeks	Clinical Significance
Systolic Blood Pressure	128 mmHg	-7.4 mmHg	Reduced CV risk
Triglycerides	144 mg/dL	-30%	Lower ASCVD risk
HDL Cholesterol	49 mg/dL	+8%	Cardioprotective
LDL Cholesterol	112 mg/dL	-7%	Reduced CV risk
HbA1c (non-diabetics)	5.7%	-0.4%	Improved glucose control
Fasting Glucose	98 mg/dL	-8 mg/dL	Lower diabetes risk
Heart Rate	71 bpm	+5 bpm	Modest increase (class effect)

Source: Jastreboff AM, et al. NEJM 2023

💚 Worth noting: The triglyceride drop (-30%) and liver fat improvement (-50%) were larger than weight loss alone would predict. Glucagon receptor activation likely contributes to the extra fat metabolism.

C-Reactive Protein and Inflammation

Retatrutide also reduced markers of systemic inflammation. C-reactive protein (CRP), a marker of cardiovascular risk, dropped by an average of 43% in the 12mg group. This may contribute to long-term health benefits separate from the metabolic improvements.

Dose-Response Relationship: Does More = Better?

The Phase 2 trial clearly showed a dose-response relationship: higher doses produced better results. But is it worth pushing to the maximum dose?

Efficacy vs Side Effects by Dose

Dose	Weight Loss at 48 Weeks	Nausea Rate
1mg	-8.7%	14%
4mg	-17.1%	27%
8mg	-22.8%	39%
12mg	-24.2%	45%

Phase 2 trial data (Jastreboff et al., NEJM 2023; nausea from posted results, ClinicalTrials.gov NCT04881760). Nausea on placebo: 11%. 4mg and 8mg nausea combine the 2mg-start and 4mg-start groups; at 8mg it was 17% with a 2mg start and 60% with a 4mg start, and the 12mg group started at 2mg.

The jump from 8mg to 12mg added only 1.4 percentage points of additional weight loss while nausea affected 45% at 12mg vs 17% (2mg start) to 60% (4mg start) at 8mg. Many patients may find 8mg offers the best balance of efficacy and tolerability. The 4mg dose remains a reasonable target for those who can't tolerate higher doses while still producing clinically significant weight loss.

💊 Clinical pearl: Not everyone needs the maximum dose. If you're achieving your goals and tolerating treatment well at 4mg or 8mg, there's no requirement to push higher. The trial protocol was designed to test the upper limits, not prescribe a one-size-fits-all approach.

Phase 3 Trial Results: TRIUMPH Program

Eli Lilly's Phase 3 program, called TRIUMPH, includes multiple trials testing retatrutide in different populations. Early results have been released for TRIUMPH-4, which focused on obesity and knee osteoarthritis.

TRIUMPH-4: 68-Week Results

This trial enrolled participants with obesity (BMI ≥30) and moderate-to-severe knee osteoarthritis. The longer duration (68 weeks vs 48 weeks in Phase 2) allowed assessment of sustained efficacy.

Dose Group	Mean Weight Loss at 68 Weeks	Pain Reduction (WOMAC)
9mg	-26.4% (~64 lbs / 29 kg)	-75.8% (pain score)
12mg	-28.7% (~71 lbs / 32 kg)	-74.3% (pain score)
Placebo	-2.1%	-40.3% (pain score)

Source: Eli Lilly Medical Information, TRIUMPH-4 (NCT05931367), efficacy estimand

The 68-week results showed continued weight loss beyond the Phase 2 endpoint, with participants on 12mg losing an average of 28.7% of their body weight. This suggests the medication continues working beyond one year without plateau.

🦵 Bonus finding: Knee osteoarthritis pain scores improved by about 74% to 76% at 9mg and 12mg, versus about 40% on placebo. The combination of weight loss and possible anti-inflammatory effects likely explains most of that improvement.

Other TRIUMPH Trials

Other Phase 3 trials in the TRIUMPH program have now reported:

TRIUMPH-1: Retatrutide in adults with obesity or overweight without diabetes, published in the New England Journal of Medicine in September 2026
TRIUMPH-2: Retatrutide in adults with obesity or overweight and type 2 diabetes, published in The Lancet in September 2026
TRIUMPH-3: Retatrutide in adults with obesity and established cardiovascular disease, completed, with results reported by Lilly in July 2026 (a separate cardiovascular outcomes trial, NCT06383390, is still running)

Visualize Your Retatrutide Journey

See how retatrutide builds up in your system over time and compare different dosing protocols.

Retatrutide Calculator Reconstitution Tool

Community & Anecdotal Results Context

Since retatrutide isn't FDA-approved, most real-world use outside trials involves unapproved gray-market product, including product sold as "compounded" even though the FDA states retatrutide cannot be used in compounding under federal law. Patients in Lilly's narrow expanded access program (NCT07629401) receive authentic Lilly product, but no outcome data from that program has been published. Online communities report mixed experiences, and anecdotal evidence has real limitations.

Common Anecdotal Reports

Appetite suppression: Most users report strong hunger reduction even at lower doses (2-4mg)
Energy levels: Mixed. Some report increased energy (possibly from glucagon), others report fatigue
GI tolerance: Wide variability. Some handle 12mg with minimal issues, others struggle at 4mg
Weight loss speed: Ranges from 1-4 lbs/week depending on dose, starting weight, and adherence
Side effect duration: Nausea typically improves within 2-3 weeks at each new dose level

⚠️ Important caveats about anecdotal data:

Retatrutide obtained outside a clinical trial or Lilly's expanded access program may vary in purity and concentration vs pharmaceutical-grade trial medication
People reporting online are self-selected (those with strong results or problems post more)
Dosing protocols outside clinical trials may differ significantly
No medical supervision or standardized outcome measurement

Until retatrutide is FDA-approved and widely available, clinical trial data remains the gold standard for understanding expected results. Anecdotal reports can provide context but shouldn't override evidence-based expectations.

What Results to Realistically Expect

Clinical trials run under controlled conditions with motivated participants, regular monitoring, and lifestyle support. Real-world results typically fall short of trial outcomes.

Trial Results vs Real-World Expectations

Scenario	Expected Weight Loss (48 weeks)	Key Factors
Best Case	22-28%	12mg dose, excellent adherence, lifestyle changes, resistance training
Typical Case	15-20%	8-12mg dose, good adherence, some lifestyle modification
Lower Response	10-15%	4-8mg max tolerated dose, moderate adherence
Minimal Response	5-10%	Low dose tolerance, poor adherence, no lifestyle changes

Factors That Affect Individual Results

Maximum tolerated dose: Not everyone can reach 12mg due to side effects
Adherence: Missing doses or inconsistent timing reduces efficacy
Baseline metabolic health: Insulin resistance, PCOS, thyroid issues affect response
Age: Metabolic rate naturally declines with age, affecting weight loss velocity
Genetics: Some people are better responders to GLP-1 medications than others
Concurrent medications: Certain drugs (antipsychotics, corticosteroids) can blunt weight loss
Sleep and stress: Poor sleep and high cortisol impair weight loss
Protein intake: Inadequate protein accelerates muscle loss

🎯 Realistic goal setting:

If you're starting at 240 lbs, aim for 30-45 lbs lost in the first year on a 8-12mg protocol with lifestyle changes. If you hit 50-60 lbs, consider that exceptional. If you only lose 15-20 lbs but feel better and improve metabolic markers, that's still a win.

Frequently Asked Questions

How much weight can you lose on retatrutide?

Clinical trial data shows average weight loss of 24.2% at 48 weeks on the 12mg dose. For someone starting at 240 pounds, that's approximately 58 pounds. Individual results vary based on dose tolerance, adherence, lifestyle factors, and genetics. Most people can expect 15-25% weight loss over one year if they reach therapeutic doses (8-12mg) and make concurrent lifestyle changes.

When do you see results with retatrutide?

Most people notice appetite suppression within the first week. Measurable weight loss (2-3%) typically appears by week 4. Significant results (8-10% loss) become evident around week 12 as you reach therapeutic doses. Maximum weight loss velocity occurs between weeks 12-24 when reaching the 8-12mg dose range. Weight continues declining through week 48 and beyond based on Phase 3 trial data.

Is retatrutide more effective than tirzepatide or semaglutide?

Trial data suggests retatrutide produces greater weight loss than tirzepatide (24.2% vs 20.9%) or semaglutide (24.2% vs 14.9%). However, these comparisons come from separate trials with different populations and durations. The triple-agonist mechanism (GLP-1/GIP/glucagon) appears to offer incremental benefit over dual-agonist (tirzepatide) or single-agonist (semaglutide) approaches. Head-to-head comparative trials are needed for definitive conclusions.

What metabolic improvements can you expect with retatrutide?

Beyond weight loss, retatrutide produces significant metabolic benefits: 30% reduction in triglycerides, 8% increase in HDL cholesterol, 7.4 mmHg decrease in systolic blood pressure, 50% reduction in liver fat, and improved glycemic control (HbA1c reduction of 0.4% even in non-diabetics). Visceral fat decreased by 42%, exceeding total weight loss percentage. These improvements occur partly from weight loss but also from direct metabolic effects of the triple-agonist mechanism.

Do retatrutide results plateau over time?

Phase 2 trial data showed no plateau at the 48-week endpoint; weight loss was still declining. Phase 3 trials extended to 68 weeks confirmed continued weight loss (28.7% at 68 weeks vs 24.2% at 48 weeks on the 12mg dose). This suggests retatrutide continues working beyond one year without the plateau seen with some other weight loss interventions. Long-term data (2+ years) will come from ongoing trials.

How much muscle do you lose on retatrutide?

DEXA scan data from the Phase 2 trial showed approximately 26% of total weight lost was lean mass (muscle, water, bone, organs). For the 12mg group losing 24 kg total, about 6.2 kg was lean mass and 17.8 kg was fat mass. This ratio (74% fat, 26% lean) is typical for significant weight loss and comparable to other GLP-1 medications. Resistance training and adequate protein intake (1.0-1.2g/kg daily) can help preserve muscle during treatment.

Does everyone respond to retatrutide?

Response varies, but the vast majority see results. In the Phase 2 trial, 100% of participants on 8mg or 12mg achieved at least 5% weight loss (the threshold for health benefits). However, some people stop because of side effects: in Phase 3 TRIUMPH-1 (Jastreboff et al., NEJM 2026; adults with obesity or overweight without diabetes), 4.1% to 11.2% of participants on 4 to 12mg discontinued due to adverse events, vs 4.6% on placebo. Real-world response will likely be more variable due to differences in dose tolerance, adherence, and individual metabolic factors. Some people are naturally better responders to GLP-1 class medications than others.

What happens when you stop retatrutide?

Weight regain after stopping GLP-1 medications is common, though data specific to retatrutide discontinuation is limited. Studies with semaglutide and tirzepatide show most people regain 50-80% of lost weight within one year of stopping if no other interventions are made. Maintaining weight loss typically requires either continuing medication long-term or implementing significant sustained lifestyle changes. This is similar to other obesity treatments; the underlying biology doesn't permanently change.

Model Your Retatrutide Protocol

Use our free calculator to visualize your dosing schedule and projected drug levels over time.

Open Retatrutide Calculator Reconstitution Tool

References

Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. [PubMed]
Eli Lilly. A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (NCT04881760). ClinicalTrials.gov. Updated 2023.
Eli Lilly. A Master Protocol to Investigate Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight, including Knee Osteoarthritis substudy (TRIUMPH-1, NCT05929066). ClinicalTrials.gov. Verified 2026-05-07.
Frias JP, Hsia S, Erichsen L, et al. Efficacy and safety of retatrutide in people with type 2 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 1b trial. Lancet. 2023;402(10411):529-544. [PubMed]
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed]
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed]
Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J Clin Endocrinol Metab. 2021;106(2):388-396. [PubMed]
Nahra R, Wang T, Gadde KM, et al. Effects of Retatrutide, a GIP/GLP-1/glucagon receptor agonist, on energy intake and expenditure. Diabetes. 2021;70(Suppl 1). [Abstract]
FDA. Guidance for Industry: Developing Products for Weight Management (Revision 1). February 2007.
Hall KD, Kahan S. Maintenance of Lost Weight and Long-Term Management of Obesity. Med Clin North Am. 2018;102(1):183-197. [PubMed]
Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published online September 29, 2026. doi:10.1056/NEJMoa2604169.
Eli Lilly Medical Information. What are the results of retatrutide from TRIUMPH-1 in participants with obesity or overweight without type 2 diabetes? (TRIUMPH-1 adverse-event table, citing the NEJM paper).
Bellido V, le Roux CW, Ekinci EI, et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet. Published online September 29, 2026. doi:10.1016/S0140-6736(26)01861-1.
Eli Lilly Medical Information. What are the preliminary results with retatrutide from TRIUMPH-4 in participants with obesity or overweight and osteoarthritis?

⚕️ Medical Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Retatrutide is an investigational medication not approved by the FDA. All clinical trial data presented is from published research and ongoing studies. Individual results vary significantly based on dose, adherence, lifestyle factors, and genetics. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication regimen. The information provided should not replace professional medical advice, diagnosis, or treatment.